Want to join the conversation?
$BCR's 3Q15 sales from surgical graft were up 4% in 3Q15. The Endovascular business sales grew 18%, excluding the royalty payment from Gore. Within the Endovascular business, biopsy products climbed 14%, driven by healthy growth across the U.S. and even better performance internationally.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.